It’s a clean sweep. Within the last two weeks, Big Tobacco, Big Pharma and Big Alcohol have all made moves into the Canadian cannabis industry:

• On Dec. 7, Marlboro cigarette maker Altria Group purchased 45% of Toronto-based Cronos Group (NASDAQ: CRON) for $1.8 billion.

• On Dec. 18, Swiss pharmaceutical giant Novartis (they own Sandoz) inked a deal with British Columbia-based Tilray Inc. to make medical cannabis products available through Novartis’ distribution network in 35 countries.

• On Dec. 20, Belgium-based Anheiser-Busch InBev partnered with Tilray to spend $100 million researching CBD and THC non-alcoholic drinks. Each company will pitch in $50 million. A-B InBev owns Budweiser, Stella Artois, Labatt’s and literally hundreds of other beer brands.

TILRAY CEO BRENDAN KENNEDY: “It’s too early to know how big cannabinoid-based beverages will be, but we think it’s a massive opportunity and it’s something we’re interested in investing aggressively in.”

Previously, Canopy Growth and Hexo Group made deals with alcohol companies Constellation Brands and Molson Coors, respectively. Constellation – which owns Corona, Mondavi and other brands – invested $4 billion in Canopy.

About the A-B InBev deal, Tilray’s CEO Brendan Kennedy stated: “It’s too early to know how big cannabinoid-based beverages will be, but we think it’s a massive opportunity and it’s something we’re interested in investing aggressively in.”

After its big week, Tilray’s stock, NASDAQ: TLRY, was up 15% to $79.

Related Articles

The Meteoric Rise of Canada’s Legal Cannabis Industry

The Top 12 Canadian Pot Stocks

The View from Vancouver: Inside Canada’s Legalization Challenge

If you enjoyed this Freedom Leaf article, subscribe to the magazine here

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2019 Freedom Leaf, Inc. The Good News in Marijuana Reform | All Rights Reserved

or

Log in with your credentials

or    

Forgot your details?

or

Create Account